8-K
FILANA THERAPEUTICS, INC. (FLNA)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
___________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 5, 2022
___________________
Cassava Sciences, Inc.
(Exact name of registrant as specified in its charter)
___________________
| Delaware | 000-29959 | 91-1911336 |
|---|---|---|
| (State or other jurisdiction<br><br>of incorporation) | (Commission<br><br>File Number) | (I.R.S. Employer<br><br>Identification Number) |
7801 N Capital of Texas Highway, Suite 260
Austin, Texas 78731
(Address of principal executive offices, including zip code)
(512) 501-2444
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
___________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
| | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b)) |
| | Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br><br>Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.001 par value | SAVA | NASDAQ Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 5, 2022, the Compensation Committee of the Board of Directors of Cassava Sciences, Inc. approved 2021 performance cash bonus awards and base salaries for each of the executive officers listed below, effective January 1, 2022.
| Name and Principal Position | 2022 Base Salary<br> | 2021 Bonus Award<br> | ||
|---|---|---|---|---|
| Remi Barbier | $ | 1,100,000 | $ | 750,000 |
| President, Chief Executive Officer | ||||
| and Chairman of the Board | ||||
| Nadav Friedmann, Ph.D., M.D. | $ | 500,000 | $ | 400,000 |
| Chief Medical Officer | ||||
| and Director | ||||
| James W. Kupiec, M.D. | $ | 400,000 | $ | 100,000 |
| Chief Clinical Development Officer | ||||
| Eric J. Schoen | $ | 425,000 | $ | 500,000 |
| Chief Financial Officer |
Item 9.01. Financial Statements and Exhibits.
| Exhibit Number | Description |
|---|
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CASSAVA SCIENCES, INC. | ||
|---|---|---|
| a Delaware corporation | ||
| Date: January 6, 2022 | ||
| By: | /s/ ERIC J. SCHOEN | |
| Eric J. Schoen | ||
| Chief Financial Officer |